Aimmune Therapeutics' PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
List view / Grid view
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
Nestlé Health Science will acquire Aimmune Therapeutics for a total value of $2.6 billion, extending the former's food allergy portfolio.
Palforzia, a peanut allergen powder, has been approved for the reduction of allergic reactions in children aged four to 17. It is not an emergency treatment but instead designed to build tolerance.